Boehringer Ingelheim GmbH 보도자료
Uninterrupted Pradaxa® Showed Less Major Bleeding than Warfarin in Atrial Fibrillation Patients Undergoing Catheter Ablation
03월 20일 17:35
Important new data from the RE-CIRCUIT® study show a better safety profile for Pradaxa® (dabigatran etexilate) compared to warfarin in atrial fibrillation (AF) patie...
First dedicated outcome trials of empagliflozin in chronic heart failure initiated
03월 20일 09:25
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the EMPEROR HF clinical trial programme was initiated. EMPEROR HF comprises two Phase...
Boehringer Ingelheim expands collaboration with Vanderbilt University to tackle some of the most difficult-to-treat cancers
03월 03일 09:40
Boehringer Ingelheim announced today a new collaboration with Vanderbilt University, Nashville, Tennessee. The multi-year program complements an already existing col...
US FDA Expands Approval of Tiotropium Respimat® for Maintenance Treatment of Asthma in Children
02월 17일 10:35
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved tiotropium Respimat® (marketed as SPIRIVA® Respimat®) for the long-ter...
Afatinib to be evaluated in combination with PD-1 inhibitor pembrolizumab in new trial for patients with squamous cell carcinoma of the lung
02월 10일 10:40
Boehringer Ingelheim today announced the initiation of a Phase II trial of afatinib* (Giotrif®) in combination with pembrolizumab (Keytruda®) for patients with local...
Jardiance® (empagliflozin) becomes first type 2 diabetes medicine in the EU to include cardiovascular death reduction data in label
01월 30일 09:55
The European Commission has approved an update to the Jardiance® (empagliflozin) label to include a change to the indication statement. Jardiance® is now indicated f...
Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review
01월 19일 11:40
Boehringer Ingelheim announced today that BI 695501, its adalimumab biosimilar candidate to Humira®*, has been accepted for regulatory review by the European Medicin...
CHMP adopts a positive opinion acknowledging that Jardiance® reduces the risk of CV death
2016년 12월 19일
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today adopted a positive opinion to update the Jardiance® (empaglifl...
Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease
2016년 12월 08일
Results from a new international survey of physicians revealed more patients with advanced non-small cell lung cancer (NSCLC) could benefit from targeted therapy bas...
Clinically meaningful data for oral nintedanib in mesothelioma presented at World Conference on Lung Cancer
2016년 12월 08일
Boehringer Ingelheim today announced that the LUME-Meso Phase II trial in patients with unresectable malignant pleural mesothelioma (MPM) met its primary endpoint of...
U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
2016년 12월 06일
The U.S. Food and Drug Administration (FDA) approved a new indication for Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults wit...
New Data Show High Adherence Rates with Pradaxa® (dabigatran etexilate) in NVAF Patients
2016년 12월 05일
Boehringer Ingelheim today announced results from a new analysis of the GLORIA™-AF Registry Program, which showed that newly diagnosed non-valvular atrial fibrillati...
Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss
2016년 11월 29일
Boehringer Ingelheim and China Southeast University Institute of Life Sciences today announced the start of a joint research project to develop new treatment approac...
Boehringer Ingelheim welcomes central role of LAMA/LABA therapy within 2017 GOLD Strategy for COPD
2016년 11월 17일
Boehringer Ingelheim welcomes the updated 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy which now positions a combination of a LAMA (lo...
Updated Phase III Results Reinforce Safety and Efficacy of Praxbind® (idarucizumab) in Urgent Situations
2016년 11월 17일
Boehringer Ingelheim announced updated results from data for 494 patients participating in the ongoing phase III RE-VERSE AD™ study, which showed that administration...
1 2 3 4 5 6 7 8 9 10 11 > »
Boehringer Ingelheim GmbH
상장여부 : 비상장
본사 소재지 : INGELHEIM, Germany
업종: 건강-제약
기업 개요:
등록된 회사소개가 없습니다.